share_log

Morgan Stanley Maintains Equal-Weight on Prime Medicine, Lowers Price Target to $21

Morgan Stanley Maintains Equal-Weight on Prime Medicine, Lowers Price Target to $21

摩根士丹利维持对Prime Medicine的同等权重,将目标价下调至21美元
Benzinga Real-time News ·  2023/01/24 09:23

Morgan Stanley analyst Matthew Harrison maintains Prime Medicine (NASDAQ:PRME) with a Equal-Weight and lowers the price target from $23 to $21.

摩根士丹利分析师马修·哈里森维持优质医药(纳斯达克:PRME)的同等权重,并将目标价从23美元下调至21美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发